Introduction {#s0005}
============

Currently, chitosan and chitosan derivatives-based composite materials are used widely in drug delivery applications [@b0005], [@b0010]. Because of their various physicochemical properties, such as biodegradability, mucoadhesion, and biocompatibility [@b0015], [@b0020], [@b0025], these polymers have shown a unique nature compared to other polymers. Chitosan (β-(1-4)-2-amino-2-deoxy-d-glucose) is a deacetylated product of the linear polysaccharide chitin, which is the second most abundant natural polymer in the world after cellulose and is commonly found in the shells of marine crustaceans and cell walls of fungi [@b0030], [@b0035], [@b0040]. The difficulties in isolating marine sources based chitosan obtained from fungal sources have been overcome; for instance, removal of proteins, calcium content, and pigments have been reported [@b0040], [@b0045].

Wound healing is a complex process [@b0050], [@b0055], [@b0060] where microbial infection can worsen the healing process [@b0065], [@b0070]. The drug-loaded porous structured biomaterials are able to overcome all the issues in wound healing [@b0075]. Chitosan sponges have been reported to have the potential for wound healing and subcutaneous implantation of the delivered drugs, proteins, growth factors, vitamins, minerals, fibroblasts, and platelets [@b0080], [@b0085], [@b0090], [@b0095], [@b0100]. However, it is expensive for people living in low-income countries.

The ultimate aim of the current study was to produce inexpensive, reproducible, and efficient wound dressing material. Accordingly, fungal chitosan, *Aloe vera* extract (AVE), and tetracycline hydrochloride (TCH) were chosen for the present study. In the previous work, silver nanoparticles loaded with FCS-AVE nanocomposite sponges exhibited good antibacterial and cell proliferation activities. Moreover, AVE incorporated composites minimized silver toxicity and exhibited synergistic activity with chitosan to enhance the proliferation of human dermal fibroblast cells [@b0105]. *Aloe vera* is a natural therapeutic plant that has been used for wound healing and against burning and inflammatory activity [@b0110]. In view of the significant amount of amino acids, glycoproteins, and other antioxidant molecules in *Aloe vera*, cell proliferation increases [@b0115]. TCH is a well-known antibiotic that controls bacterial growth by way of inhibiting enzymatic reactions, protein and ribosome synthesis, and altering the cytoplasmic membrane synthesis. Because of these benefits, TCH is still being used in wound dressing materials [@b0120], [@b0125].

With this background, the fungal chitosan-based FCS-TCH and FCS-AVE-TCH composites were developed, their physicochemical properties evaluated, antibacterial activity and *in vitro* drug release studied. In addition, the composites were analyzed *in vitro* drug release to the Vero cells with respect to their response to wound dressing materials.

Material and methods {#s0010}
====================

Material {#s0015}
--------

Tetracycline hydrochloride (TCH) and Muller Hinton agar (MHA) were purchased from HiMedia Laboratories (Mumbai, India); MTT (3-(4,5-Dimethyl-2-thiazolyl)-2,5-diphenyl tetrazolium Bromide), acridine orange (AO) and ethidium bromide (EB) was procured from Sigma Aldrich (Mumbai, India); Sodium hydroxide and Lysozyme were obtained from Sisco Research Laboratories Pvt. Ltd. (Chennai, India); Acetic acid (AA) was procured from SD Fine Chem Limited (Chennai, India). All the chemicals were used without further purification. The low molecular weight fungal chitosan, with the degree of deacetylation 80.85%, was isolated from the fungus *Cunninghamella elegans* [@b0105].

Preparation of FCS-TCH and FCS-AVE-TCH composite sponges {#s0020}
--------------------------------------------------------

Fungal chitosan (0.5 g) was dissolved in 50 mL of 1% acetic acid solution. Then 0.5 g/L of aqueous soluble TCH was added into the fungal chitosan (FCS) solution under continuous stirring (800 rpm) for 5 h and the FCS-TCH composite solution was prepared. Preparation of AVE and FCS-AVE composites has been discussed in previous studies [@b0105]. In brief, 0.2% of AVE was added drop-wise into the completely dissolved FCS solution stirring continuously for 2 h, and subsequently, the TCH solution was added. The stirring was continued for another 5 h. The one milliliter of composite solution was then poured into a 24-well plate (15.5 dia. x 18 deep mm), freeze at −50 °C, lyophilized (FD--10 M Freeze Dryer, LARK, India), and the sponges obtained (15.5 dia. x 10 mm height) were kept at −20 °C until further use.

Characterization {#s0025}
----------------

The FCS, TCH, AVE, FCS-TCH, FCS-AVE, and FCS-AVE-TCH composite solutions were examined under UV--Visible spectroscopy at a spectral range of 200--700 nm. The functionalities of all the composite sponge materials were recorded by using FTIR-ATR spectrometer (PerkinElmer-spotlight 400 FT-IR Imaging system, India) with a spectral range of 4000--450m cm^−1^. Furthermore, the gold sputter coated composite sponges were observed with a scanning electron microscope (Hitachi S3400, Japan), precision at 15.0 keV.

Porosity measurement {#s0030}
--------------------

The porosity of fungal chitosan-based composite sponge was analyzed by the liquid displacement method using ethanol [@b0185]. A Vernier caliper was used to measure the dimensions of the sponges and the volume (V) was calculated. The initial weight (W~i~) of the lyophilized sponges were recorded, and they were immersed into a known volume of ethanol in a graduated cylinder for 24 h, and the final weight (W~f~) of the wet sponges was recorded. Accordingly, porosity was calculated using Eq. [(1)](#e0005){ref-type="disp-formula"}. The experimental data were obtained in triplicate and the results were shown in mean ± standard deviation (n = 3).$$\begin{array}{l}
{\%\mspace{6mu}\text{of\ porosity} = \left( \frac{(W_{f} - W_{i})}{(\rho\text{ethanol} \times \text{V})} \right) \times 100} \\
{\rho\text{ethanol:\ density\ of\ ethanol.}} \\
\end{array}$$

Water sorption and moisture retention capacity {#s0035}
----------------------------------------------

Water sorption capacity of FCS-TCH and FCS-AVE-TCH sponges were evaluated at different time intervals, viz., 1 h, 2 h, 3 h, 4 h, 5 h, and 6 h in deionized water at room temperature. All the dry sponges (W~d~) were pre-weighed and then immersed into the buffer solution, the wet sponges (W~w~) were weighed at each interval, and the excess amount of water was gently removed by using tissue paper. The experiment was performed thrice. The following formula [(2)](#e0010){ref-type="disp-formula"} was used to calculate the water sorption capacity. The results were expressed as the mean ± standard deviation (n = 3).$$\%\mspace{6mu}\text{of\ water\ sorption} = \frac{W_{w} - W_{d}}{W_{d}} \times 100$$

For evaluating the moisture retention capacity, the composite sponges were evaluated using the procedure as detailed by Liang et al. [@b0180]. In brief, the dry sponges (W~d~) were immersed in deionized water for 2 h, and the wet sponges (W~w~) were placed in a glass petri dish at the room temperature. The moisture retention capacity was recorded each hour up to reaching their dry weight. The results were expressed as the mean ± standard deviation (n = 3).

Blood absorption assay {#s0040}
----------------------

Blood absorption assay was carried out according to Hajosch et al. 2009 [@b0190] with some modification. In brief, the erythrocyte was isolated from human blood and was stabilized with citrate-phosphate-dextrose with adenine solution, and then it was diluted with an isotonic saline solution (1:4 ratio). The 40--56% of red blood cells was used for blood absorption assay. The sponges were gently introduced into the blood surface for 20 s. Subsequently, the sponges that had absorbed the blood were placed on the Whatman filter paper grade 1(Sigma Aldrich, Mumbai, India) for 1 min to remove the excess amount of blood. The sponges were weighed before being introduced to the blood (M~d~) and after removing excess amount of blood (M~w~). Blood absorption capacity (BAC) was calculated by the formula in Eq. [(3)](#e0015){ref-type="disp-formula"}*.* The experiment was repeated thrice and the data were expressed as the mean ± standard deviation (n = 3).$$\mathit{BAC} = \frac{M_{w} - M_{d}}{M_{d}}$$

Biodegradation assay {#s0045}
--------------------

The biodegradation (BD) of FCS-AVE-TCH composite sponge was determined by Su et al. 2017 [@b0195] with some modification. In brief, the FCS-AVE-TCH sponges were immersed into the PBS solution (pH = 7.4) containing 50 µg/mL of lysozyme enzyme (15,000 U/mg) at 37 °C for 15 days. At each predetermined interval (5, 10, and 15 days), the immersed sponges were taken out, washed with deionized water, and freeze-dried. The biodegradability of FCS-AVE-TCH sponges was calculated using Eq. [(4)](#e0020){ref-type="disp-formula"}.$$\mathit{BD} = \frac{(W_{0} - W_{t})}{W_{0}} \times 100\%$$where W~0~ was the initial weight of FCS-AVE-TCH, and the weight after freeze-drying was (W~t~). The degradation percentage was expressed as the mean ± standard deviation (n = 3).

*In vitro* drug release {#s0050}
-----------------------

To determine the TCH release from FCS-TCH and FCS-AVE-TCH, the composite sponges were immersed in a dissolution bath containing 20 mL Phosphate buffer (pH 7.4) at 37 °C under shaking condition (200 rpm). At predetermined time intervals (10, 20, 30, 40, 50, 60, 120, 180, 240, 300, and 360 min) 2 mL of samples were drawn from the dissolution bath and an equal amount of fresh buffer was replaced each time to maintain the equilibrium constant. The volume of the drawn sample was examined with a UV--Visible spectrophotometer at an absorbance of 356 nm and the results recorded. The concentration of TCH release was calculated using the linear curve to obtain values from known concentrations of TCH. The cumulative drug release percentage was calculated and expressed as the mean ± standard deviation (n = 3). The obtained data were fitted with various mathematical models for drug release, such as zero order, first order, Korsmeyer--Peppas, Hixson--Crowell, and Higuchi models, as followed by Dhanavel et al. 2017 [@b0130].

*In vitro* antibacterial activity {#s0055}
---------------------------------

The antibacterial activity of fungal chitosan and composite sponges were tested against both the Gram-positive (*Staphylococcus aureus* ATCC 33592 and *Bacillus subtilis* ATCC 55614) and Gram-negative bacteria (*Klebsiella pneumoniae* ATCC 13884 and *Escherichia coli* ATCC 11229). The bacterial cultures were incubated in freshly prepared nutrient broth medium at 37 °C overnight. The adjusted bacterial suspensions (10^7^ cells/mL) were uniformly spread on an MHA plate; then the various composite sponges were placed on the bacteria inoculated plates and incubated overnight at 37 °C. After incubation, the zone of inhibition around the composite sponges was measured in terms of millimeters. The experiment was done in triplicate, the data were expressed as the mean ± standard deviation (n = 3).

*In vitro* cell viability and observation of cell morphology {#s0060}
------------------------------------------------------------

The FCS and composites-treated Vero cells were tested for cell viability by using MTT assay. The Vero cells were grown in DMEM medium supplemented with 10% FBS and antibiotics, penicillin (100 µg/mL) and Streptomycin (100 µg/mL). The 200 µL of Vero cells (1 × 10^5^) were seeded on a 96-well plate, incubated in a humidified chamber overnight at 37 °C with an atmosphere containing 5% CO~2~, and the media were discarded. Twenty µL of FCS, TCH, AVE, FCS-TCH, FCS-AVE, and FCS-AVE-TCH were added to each well of the plate, and the plates were incubated for 24 h. For the control, the cells were maintained without any of the above-mentioned components. The samples containing the media were changed and fresh media used, 20 µL of MTT was added to each well, and the incubation continued for 6 h. After that, the medium was removed and 200 µL DMSO was added to each well to dissolve the formazan, and then the plates were measured at an absorbance of 570 nm to calculate the percentage of cell viability. Furthermore, the Vero cells seeded on a 6-well plate were treated with the composites mentioned earlier, and the morphology of the cells was observed (20X magnification) under a fluorescence microscope (EVOS Floid cell imaging station, Thermo Fisher Scientific -- USA) by using the dual staining (AO/EB) technique [@b0135].

Statistical analysis {#s0065}
--------------------

All the experimental data were expressed as means ± SD. The cell viability data were analyzed using one-way analysis of variance (ANOVA) with Prism software 6.00 (Graph Pad Software for Windows, La Jolla, CA, USA), followed by Dunnett's post hoc test to depending on the homogeneity of the variance test. In this experiment, *P \<* 0.05 was considered statistically significant. The antibacterial activity was examined using the one way ANOVA and the least significant difference was at 5%. These tests were used to compare the means of the zone using the IBM SPSS version 20.1 (IBM SPSS statistics for windows, version 22.0. Armonk, NY: IBM Corp).

Results and discussion {#s0070}
======================

Characterization of composites {#s0075}
------------------------------

[Fig. 1a](#f0005){ref-type="fig"} shows the UV--Visible spectra of the composites; the FCS shows absorption peaks at 200--205 nm assigned to the π → π∗ transition [@b0140]. The absorption spectrum of TCH exhibited three absorption peaks at 218, 273, and 356 nm corresponding to π→ π∗, π → π∗, and n → π∗ transitions [@b0145]. AVE showed absorbance peaks at 290 and 350 nm corresponding to π → π∗ and n → π∗ transitions. The absorption peak of the FCS-AVE combination appeared at 230 nm. The FCS-TCH combination showed all the respective peaks of TCH with lower intensity. The combination of FCS-AVE-TCH exhibits absorption peaks at 230 nm along with the TCH peaks ([Fig. 1a](#f0005){ref-type="fig"}), which shows that all the major functional groups were present in the composites.Fig. 1aUV--Visible spectrum. FCS -- Fungal chitosan, TCH -- Tetracycline hydrochloride, AVE -- *Aloe vera* extract, and the combination of FCS-TCH, FCS-AVE, FCS-AVE-TCH composites.

Attenuated total reflectance Fourier transform infrared spectroscopy (ATR-FTIR) {#s0080}
-------------------------------------------------------------------------------

The ATR-FTIR spectra of FCS, TCH, AVE, FCS-AVE, FCS-TCH, and FCS-AVE-TCH are shown in the [Figs. 1b](#f0010){ref-type="fig"} and [1c](#f0015){ref-type="fig"}. The fungal chitosan spectra showed the characteristic band at 1637 cm^−1^, assigned to C000000000000 000000000000 000000000000 111111111111 000000000000 111111111111 000000000000 000000000000 000000000000O stretching frequency, the N---H bending frequency at 1555 cm^−1^ assigned to the amine and amide II bands, and the medium intensity bands at 3406 cm^−1^ and 3273 cm^−1^ attributed to ---OH and ---NH stretching frequency [@b0040], [@b0150]. The FTIR spectrum of tetracycline shows the characteristic peak at 1660 cm^−1^ corresponding to the amide carbonyl group. The appearance of a doublet at 1601 cm^−1^ and 1610 cm^−1^ accounted for the N---H bending frequency, with the N---H band appending with the O---H band at 3300--3313 cm^−1^ [@b0155], [@b0160]. The AVE spectrum exhibited the band at 3344 cm^−1^, attributed to the N---H stretching frequency. A weak band at 2926 cm^−1^ is assigned to CH stretching frequency, and the sharp band that appears at 1611 cm^−1^ indicates the presence of the carbonyl groups. The spectra of FCS-TCH and FCS-AVE-TCH composite are shown in [Fig. 1c](#f0015){ref-type="fig"}. When TCH and AVE were added to fungal chitosan, the ATR spectra did not exhibit any substantial changes, because the concentrations of the TCH and AVE were low and evenly assimilated into the composite sponge. The PVA/Chitosan/Tetracycline hydrochloride wound dressing mats did not show any significant difference in ATR spectra [@b0125]. The results suggest that the amide group of the fungal chitosan are responsible for the formation of the intermolecular hydrogen bonding.Fig. 1bFTIR -- ATR Spectra of TCH -- Tetracycline hydrochloride, AVE -- *Aloe vera* extract and FCS -- Fungal chitosan.Fig. 1cFTIR -- ATR spectra of FCS-AVE-TCH -- Fungal chitosan incorporated *Aloe vera* extract bounded Tetracycline hydrochloride and FCS-TCH -- Fungal chitosan bounded tetracycline hydrochloride.

SEM analysis {#s0085}
------------

The SEM image of FCS and FCS-reinforced composite sponges are shown in [Fig. 2](#f0020){ref-type="fig"}. The porous structure of the FCS sponge was shown to be compact, whereas TCH added FCS-TCH composite sponges displayed less compact porous structure. The AVE added FCS-AVE-TCH sponge as present in the well-interconnected porous structure is shown in [Fig. 2](#f0020){ref-type="fig"}. The results exhibit that AVE promotes the formation of the porous structure without destruction.Fig. 2SEM image of porous structured sponges.

Porosity measurement {#s0090}
--------------------

The porosity of the composite sponges was evaluated by the liquid displacement method. FCS and FCS-TCH sponges showed porosity of 56.44% and 55.87%, respectively. FCS-AVE-TCH sponges had a porosity of 68.74%, which was higher than the control sponges ([Fig. 3a](#f0025){ref-type="fig"}). Hence, the higher the porosity in the FCS-AVE-TCH composite, the more the AVE extract can bind with the free amine and hydroxyl groups of chitosan as shown by the ATR-FTIR spectral analysis. The development of fungal chitosan and *Aloe vera* extract-based antibacterial drug loaded wound dressing composite sponges have the advantages of a porous structured morphology that helps in enhancing the gaseous exchange and absorption of wound exudates [@b0180] by the way it releases active molecules to the wounded skin.Fig. 3aPorosity of fungal chitosan and fungal chitosan composite sponges.

Water sorption and moisture retention capacity {#s0095}
----------------------------------------------

Water sorption is a significant characteristic of good wound dressing material where it has to absorb the water that the wound exudates and further release the drug in an osmotic manner. Fungal chitosan sponges exhibited good sorption capacity ([Fig. 3b](#f0030){ref-type="fig"}). At the 4th h, FCS-TCH and FCS-AVE-TCH sponges showed 1476.73% and 1652.73% sorption capacity, respectively; furthermore, the amount of absorption was maintained until the end of the experiment. The water absorption behavior of composite sponges increased with respect to increasing time, and a constant amount was maintained after reaching the equilibrium constant. The swelling behavior of wound dressing materials depending on the porosity and the highly porous material's absorption rate was higher than the material with low porosity.Fig. 3bPercentage of water sorption capacity of composite sponges.

The FCS-TCH and FCS-AVE-TCH sponges were tested for their moisture retention capacity ([Fig. 3c](#f0035){ref-type="fig"}). The FCS-TCH and FCS-AVE-TCH composites sponges attained their own dry weight at 6 and 8 h, respectively. The moisture retention capacity was different at each hour between the two composite sponges. The FCS-AVE-TCH had a better organized porous structure than the FCS-TCH sponges, seen in the different initial absorption capacity of the sponges ([Fig. 3c](#f0035){ref-type="fig"}).Fig. 3cPercentage of water retention capacity of composite sponges.

Blood absorption assay {#s0100}
----------------------

The FCS-TCH and FCS-AVE-TCH composite sponges were tested *in vitro* against red blood cells (RBC) by absorption assay ([Fig. 3d](#f0040){ref-type="fig"}). It was observed that FCS-TCH sponges absorbed 24.88 times its own weight, whereas the FCS-AVE-TCH sponges absorbed 25.08 times its own weight. Blood uptake capacity of the sponges would be helpful in avoiding blood loss at the time of bleeding and also promote the blood flow between the wound skins [@b0190]. However, the developed sponges had not absorbed the blood like deionized water and need further detailed optimization and studies.Fig. 3d*In vitro* blood absorption capacity of fungal chitosan based composite sponges FCS-TCH and FCS-AVE-TCH.

Biodegradation of FCS-AVE-TCH sponges {#s0105}
-------------------------------------

The biodegradation property of FCS-AVE-TCH sponges was evaluated with lysozyme as shown in [Fig. 3e](#f0045){ref-type="fig"}. The biodegradation rate of sponges was 25% (5th day), 41.6% (10th day), andFig. 3e*In vitro* degradation of FCS-AVE-TCH composite sponge.

55% (15th day). The FCS-AVE-TCH sponges have shown good biodegradable property, which could be used for wound dressing application.

*In vitro* drug release {#s0110}
-----------------------

[Fig. 3f](#f0050){ref-type="fig"} shows that the accumulated TCH release from FCS-TCH and FCS-AVE-TCH sponges during the 6 h under *in vitro* condition. The TCH release was increasing gradually from the composite with respect to increasing the time due to the strong hydrophilic affinity of the drug [@b0125]. The drug release profile from the polymeric matrix was fitted with various mathematical models, such as zero order, first order, Korsmeyer--Peppas, Hixson--Crowell, and Higuchi models, as shown in [Fig. 4](#f0055){ref-type="fig"}(a)--(e). The TCH release was determined by the R squared value obtained from the kinetic fitting of drug release, and based on the highest regression coefficient, the better drug release kinetic model was proposed. Both the FCS-TCH and FCS-AVE-TCH sponges initially exhibited 17% and 25% in drug release due to the swelling of the polymer composite and enhanced the diffusion of the drug, which is present on the surface of the composites [@b0130].Fig. 3fTetracycline hydrochloride cumulative release of FCS-TCH and FCS-AVE-TCH composite sponges.Fig. 4Fitting of drug release to the different kinetic model. Zero order **--** a, First order -- b, Koresmeyer-Peppas-c, Hixson-Crowell -- d and Higuchi -- e.

The TCH release from the FCS-TCH composite was best fitted with the Higuchi model (r^2^ = 0.876) compared to the others, and FCS-AVE-TCH composite was best fitted with zero order release (r^2^ = 0.951) and the Higuchi model (r^2^ = 0.948), whereas the release of the water-soluble drug was better fitted with the Higuchi model [@b0165]. The TCH release from FCS-AVE-TCH composite did not show significant difference among the kinetic drug release models, and it does release the drug by diffusion and swelling mechanisms. The TCH release of FCS-AVE-TCH fitted with the specifically developed drug release kinetic model (Korsmeyer-Peppas) from the polymer matrix showed the *R*^2^ value at 0.9278. The release exponent (n = 0.162) indicated a Fickian diffusion; the previous reports of PVA and chitosan-based nanofiber matrix also reported the release of TCH in the same manner [@b0125]. With this background, the FCS-AVE-TCH composite sponges released the drug in a constant manner, which is good for wound dressing applications.

*In vitro* antibacterial activity {#s0115}
---------------------------------

FCS, FCS-TCH, and FCS-AVE-TCH sponges were tested for antibacterial activity against Gram-positive and Gram-negative bacteria. FCS sponges showed lesser inhibitory actions against both the bacteria. But the FCS-TCH and FCS-AVE-TCH sponges exhibited maximum inhibitory action against *Bacillus subtilis, Staphylococcus aureus, Escherichia coli*, and *Klebsiella pneumoniae* by way of antibiotic drug release. Comparatively, the FCS-AVE-TCH sponges displayed substantial activity in terms of the zone of inhibition, with 27 ± 0.5 mm, 28 ± 0.6 mm, 27.53 ± 0.50 mm, and 27 ± 1.0 mm, respectively ([Fig. 5](#f0060){ref-type="fig"} and [Table 1](#t0005){ref-type="table"}). The FCS sponges showed inhibitory activity against both Gram-positive and Gram-negative bacteria because of the low molecular weight of chitosan [@b0070], [@b0105], [@b0170]. Further, the FCS-TCH and FCS-AVE-TCH sponges exhibited substantial antibacterial activity because of TCH, which is a well-established antibacterial drug [@b0065]. Moreover, microporous structured sponges enhanced the antibacterial activity by the mechanism of absorbing of water and releasing of the antibacterial drugs through the diffusion process [@b0200].Fig. 5Photographic image of chitosan and composites sponges antibacterial activity.Table 1Antibacterial activity of fungal chitosan and fungal chitosan composite sponges.*Bacillus sbtilisStaphylococus aureusEscherchia coliKlebsiella pnemoniae*Zone of inhibition in millimeterFCS17.03 ± 0.65^b^19 ± 1^a^18.5 ± 0.82^ab^15.7 ± 1.26^c^FCS-TCH20.0 ± 1.4^d^22.0 ± 1.4^c^26.17 ± 1.53^a^24.5 ± 0.5^b^FCS-AVE-TCH27.0 ± 0.5^b^28.0 ± 0.6^a^27.53 ± 0.50^ab^27.0 ± 1^b^[^1]

*In vitro* cell viability {#s0120}
-------------------------

To determine the cell viability of FCS, FCS-TCH, and FCS-AVE-TCH composites treated with Vero cells, FCS-TCH and FCS-AVE-TCH composites were evaluated using *in vitro* studies, and they revealed that both the composites and individual constituents did not show any decreasing percentage of cell viability compared with control; instead, they increased the proliferation of cell numbers. This study also proved that the 0.5 g/L TCH loaded FCS (1%)-AVE (0.2%) did not induce any toxicity, while it maintained higher cell viability and also increased cell proliferation compared to control ([Fig. 6a](#f0065){ref-type="fig"}).Fig. 6aCell viability (%) of Chitosan composite sponges treated Vero cells. Fungal Chitosan (FCS), *Aloe vera* extract (AVE), Fungal chitosan and *Aloe vera* extract (FCS-AVE), Fungal chitosan and *Aloe vera* extract with Tetracycline hydrochloride (FCS-AVE-TCH). Values are expressed mean ± SD. Each experiments were repeated thrice, ^\*\*\*^*P* \< 0.001 (Control vs FCS-AVE-TCH) and (Control *vs* FCS-TCH), ^\*\*^*P* \< 0.01 (Control *vs* FCS) and (Control *vs* AVE).

In addition, the morphological changes of Vero cells were evaluated by the dual staining (Ao/EB) technique under the fluorescence microscope. The results showed that the cells had no changes in morphology when observed under a fluorescent microscope. After the treatment with the composites, the cell viability was significantly increased when compared to control ([Fig. 6b](#f0070){ref-type="fig"}). The FCS-TCH composites were nontoxic to the normal cells but completely inhibited bacterial development. The bacterial cellulose composites delivered 0.5 g/L of tetracycline hydrochloride to the HEK293 cell line, and no adverse effects were observed [@b0175].Fig. 6bMorphological observation Fungal Chitosan (FCS), *Aloe vera* extract (AVE), Fungal chitosan and Aloe vera extract (FCS-AVE) and Fungal chitosan, *Aloe vera* extract with Tetracycline hydrochloride (FCS-AVE-TCH) composites treated Vero cells staining with AO/EB and observed under fluorescence microscope with 20× magnification.

Conclusions {#s0125}
===========

Porous, micro-fibrous structure composite sponges were prepared with a fungal chitosan- reinforced *Aloe vera* extract and associated with tetracycline hydrochloride. The composite sponges delivered antibiotic by way of *in vitro* drug delivery efficiently and displayed *in vitro* antibacterial activity while enhancing cell proliferation with the help of the natural wound healing agent AVE. Based on the review of the literature, a porous structured chitosan composite will enhance wound healing property by way of proper oxygen supply, good absorption of wound exudates, and enhancement of epidermal growth factor. Hence, these findings indicate that the FCS-AVE-TCH sponges could be used as a potential cost-effective wound dressing material.
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[^1]: Values represent the mean ± SD of three replicates. Values followed by uppercase letters in a column are significant differences (*P* \< 0.05) among the groups.
